These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32666165)

  • 1. Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study.
    de Valk HW; Feher M; Hansen TK; Jendle J; Koefoed MM; Rizi EP; Zimmermann E; Fadini GP
    Diabetes Ther; 2020 Sep; 11(9):2159-2167. PubMed ID: 32666165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study.
    Harris SB; Ajala O; Bari B; Liutkus J; Hahn J; Martyn O; Zwicker D
    Diabetes Ther; 2021 Jun; 12(6):1689-1702. PubMed ID: 33932223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study.
    Fadini GP; Feher M; Hansen TK; de Valk HW; Koefoed MM; Wolden M; Zimmermann E; Jendle J
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5977-5990. PubMed ID: 31397845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry.
    Bohn B; Zimmermann A; Wagner C; Merger S; Dunstheimer D; Kopp F; Gollisch K; Zindel V; Holl RW;
    Diabetes Res Clin Pract; 2017 Jul; 129():52-58. PubMed ID: 28505544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemic Control in People with Type 2 Diabetes Treated with Insulin Degludec: A Real-World, Prospective Non-interventional Study-UPDATES Saudi Arabia.
    AlMalki MH; Aldesokey H; Alkhafaji D; Alsheikh A; Braae UC; Lehrskov LL; Magawry W; Yahia M; Haroun A
    Adv Ther; 2023 Feb; 40(2):568-584. PubMed ID: 36417058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.
    Agesen RM; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen T; Juhl CB; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
    BMC Endocr Disord; 2019 Jul; 19(1):78. PubMed ID: 31337371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study.
    Fadini GP; Giordano C; Salvi L; Nicolucci A;
    Diabetes Ther; 2020 Dec; 11(12):2909-2920. PubMed ID: 33011923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials.
    Dżygało K; Golicki D; Kowalska A; Szypowska A
    Acta Diabetol; 2015 Apr; 52(2):231-8. PubMed ID: 25430705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.
    Kerlan V; Gouet D; Marre M; Renard É
    Ann Endocrinol (Paris); 2013 Dec; 74(5-6):487-90. PubMed ID: 23978337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin degludec. Uncertainty over cardiovascular harms.
    Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
    Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study.
    Lane W; Faurby M; Husemoen LLN; Markovich DL; Rathor N; De Block C
    Diabetes Ther; 2021 Dec; 12(12):3067-3077. PubMed ID: 34637112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting.
    Zhou FL; Nicholls C; Xie L; Wang Y; Vaidya N; Meneghini LF
    Endocrinol Diabetes Metab; 2019 Jul; 2(3):e00073. PubMed ID: 31294087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy.
    Langer J; Wolden ML; Shimoda S; Sato M; Araki E
    Diabetes Ther; 2019 Aug; 10(4):1347-1356. PubMed ID: 31168694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Real-World, Prospective, Non-interventional Study of Adults with T2D Switching to IDegAsp from Glargine U100 or U300 in Japan.
    Shigiyama F; Liu L; Nordahl H; Suzuki R; Yamamoto Y; Hirose T
    Diabetes Ther; 2021 Sep; 12(9):2405-2421. PubMed ID: 34304385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials.
    Bajaj HS; Ásbjörnsdóttir B; Bari TJ; Begtrup K; Vilsbøll T; Rosenstock J
    Diabetes Obes Metab; 2024 Jul; ():. PubMed ID: 38951942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.
    Nicolucci A; Ceriello A; Di Bartolo P; Corcos A; Orsini Federici M
    Diabetes Ther; 2020 Mar; 11(3):573-584. PubMed ID: 31873857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Cost Implications of Insulin Degludec in Patients with Type 1 Diabetes and Problematic Hypoglycemia: A Quality Improvement Project.
    Karamat MA; Dar S; Bellary S; Tahrani AA
    Diabetes Ther; 2018 Apr; 9(2):839-849. PubMed ID: 29549574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.